Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hype...
Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout
About this item
Full title
Author / Creator
Publisher
Bridgewater, NJ: EM Inc USA
Journal title
Language
English
Formats
Publication information
Publisher
Bridgewater, NJ: EM Inc USA
Subjects
More information
Scope and Contents
Contents
Abstract Background: Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout. Objective: The purpose of this review was to summarize available information about the clinical use...
Alternative Titles
Full title
Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_733866996
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_733866996
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2009.11.033
